JPRN-jRCT2080221314未知3 期
Phase III Long-Term Clinical Study of CSG452(RG7201) in Patients with Type 2 Diabetes. -Long-term Study in Monotherapy
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 192
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Has been diagnosed with type 2 diabetes
- •-Has been receiving treatment with only diet and exercise therapy
- •-HbA1c (Japanese Diabetes Society [JDS] value) >=6.5% and <10.0%
- •-Body mass index (BMI) >=18.5 kg/m2 and <45.0 kg/m2
排除标准
- •Had the following history and/or complications within 24 weeks of tests for screening test
- •-Acute diabetic complications such as diabetic ketoacidosis or hyperglycemic hyperosmolar coma
- •-Acute coronary disease (acute myocardial infarction, unstable angina, etc.) or stroke
- •-Recurrent genitourinary tract infection, defined as two or more episodes of complicated or uncomplicated cystitis or pyelonephritis
- •-Impaired hepatic function
- •-Impaired renal function
研究者
相似试验
未知
3 期
Phase III Long-Term Combination Therapy of CSG452(RG7201) in Patients with Type 2 DiabetesType 2 diabetesJPRN-jRCT2080221315Chugai Pharmaceutical Co., Ltd.565
未知
2 期
Phase II-III Clinical Study of CSG452(RG7201) in Patients with Type 2 DiabetesType 2 diabetesJPRN-jRCT2080221312Chugai Pharmaceutical Co., Ltd.220
已完成
3 期
PRASTRO-IIIJPRN-jRCT2080224080DAIICHI SANKYO Co.,Ltd.235
未知
3 期
Phase III Clinical Study of AJG522 : Studies of safety and efficacy of AJG522 as a colon preparation agent for colonoscopy - Comparative study with MGV-5Patients scheduled for colonoscopyJPRN-jRCT2080221438Ajinomoto Pharmaceuticals Co., Ltd.
已完成
2 期
Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus AureusSkin InfectionNCT01593761CrystalGenomics, Inc.20